Aurobindo Receives FDA Approval for Dicloxacillin Sodium Capsules USP, 250mg and 500mg

East Windsor - Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Dicloxacillin Sodium Capsules USP, 250mg and 500mg.

Aurobindo Pharma's Dicloxacillin Sodium Capsules are an AB-rated generic equivalent to the reference listed drug (RLD), Pathocil Capsules, manufactured by Wyeth Ayerst Laboratories.

Contact:

Tel: [phone]

(C) 2022 Electronic News Publishing, source ENP Newswire